Albert Bourla's holdings in Pfizer show a strong belief in the company’s future. As of February 2023, his shares were valued at over $29 million, significantly made up of common stock and stock appreciation rights. This was a peak period...

Albert Bourla's holdings in Pfizer show a strong belief in the company’s future. As of February 2023, his shares were valued at over $29 million, significantly made up of common stock and stock appreciation rights. This was a peak period for his holdings, indicating his confidence in the company, despite some ups and downs in the broader market. In recent years, he hasn't sold large amounts of stock, suggesting a long-term investment strategy. He has made substantial investments in shares over his career, but fluctuations in the share price have influenced the total value of his holdings, reflecting the changing tides in the pharmaceutical industry. His engagement with the company's stock further aligns his interests with those of other shareholders.